fluoxetine and Weight Gain studies

Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.

Research Excerpts

Excerpt	Relevance	Reference
"To determine whether fluoxetine can promote recovery and prolong time-to-relapse among patients with anorexia nervosa following weight restoration."	9.12	Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial. ( Attia, E; Carter, JC; Devlin, MJ; Kaplan, AS; Olmsted, M; Parides, M; Pike, KM; Roberto, CA; Rockert, W; Walsh, BT; Woodside, B, 2006)
"These results suggest that fluoxetine coadministration is clinically ineffective and cannot attenuate olanzapine-induced weight gain."	9.10	Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. ( Fuchs, C; Gil-Ad, I; Maayan, R; Pashinian, A; Poyurovsky, M; Schneidman, M; Weizman, A, 2002)
"Significant weight gain is a side effect associated with olanzapine treatment in some patients."	9.10	Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. ( Bogenschutz, M; Bustillo, JR; Hammond, R; Keith, S; Lauriello, J; Parker, K; Rowland, L, 2003)
"This study offers preliminary evidence that fluoxetine may be useful in improving outcome and preventing relapse of patients with anorexia nervosa after weight restoration."	9.09	Double-blind placebo-controlled administration of fluoxetine in restricting- and restricting-purging-type anorexia nervosa. ( Deep, D; Hsu, LK; Kaye, WH; McConaha, C; Nagata, T; Plotnicov, KH; Sokol, MS; Weise, J; Weltzin, TE, 2001)
"Patients (N = 284) with major depressive disorder (DSM-IV) were randomly assigned to double-blind treatment with fluoxetine (N = 92), sertraline, (N = 96), or paroxetine (N = 96) for a total of 26 to 32 weeks."	9.09	Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. ( Fava, M; Hoog, SL; Judge, R; Koke, SC; Nilsson, ME, 2000)
"Adding the atypical neuroleptic risperidone to a serotonin reuptake inhibitor (SRI) has benefited patients with treatment-refractory obsessive-compulsive disorder (OCD)."	9.09	Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. ( Elliott, MA; Koran, LM; Ringold, AL, 2000)
"We tested whether 14 wk of dexfenfluramine (30 mg) or fluoxetine (40 mg) treatment would prevent weight gain after subjects quit smoking."	9.08	Efficacies of dexfenfluramine and fluoxetine in preventing weight gain after smoking cessation. ( el-Khoury, A; Goldberg, H; McDermott, J; Pingitore, R; Spring, B; Wurtman, J; Wurtman, R, 1995)
"The effect of fluoxetine hydrochloride, a 5-HT uptake inhibitor (60 mg/day PO), in preventing weight gain associated with nicotine reduction was investigated in participants in a double-blind, placebo-controlled smoking-cessation trial."	9.07	Effects of fluoxetine on weight gain and food intake in smokers who reduce nicotine intake. ( Lowenbergh, JM; Morrell, EM; Pomerleau, CS; Pomerleau, OF, 1991)
" We compared the effects of chronic treatment with the preferential nNOS inhibitor 7-nitroindazole (7-NI) with those evoked by the conventional antidepressant fluoxetine on alterations that are considered as markers of depression (immobility in the forced swimming test, FST, decreased body weight gain and increased plasma corticosterone concentration) and cardiovascular changes caused by CVS."	7.81	Effects of nitric oxide synthesis inhibitor or fluoxetine treatment on depression-like state and cardiovascular changes induced by chronic variable stress in rats. ( Almeida, J; Crestani, CC; Duarte, JO; Oliveira, LA, 2015)
"This report describes a case of 12-year-old identical twins with anorexia nervosa, one of whom was treated with olanzapine and the other with fluoxetine, while undergoing family therapy."	7.78	Differential weight restoration on olanzapine versus fluoxetine in identical twins with anorexia nervosa. ( Boutelle, K; Cromley, T; Duvvuri, V; Kaye, WH; Klabunde, M, 2012)
"Weight gain during olanzapine/fluoxetine combination (OFC) therapy is very common."	7.77	Early weight gain as a predictor of substantial weight gain with olanzapine/fluoxetine combination: an analysis of 2 adult studies in treatment-resistant depression. ( Case, M; Degenhardt, EK; Jamal, HH; Tormey, S, 2011)
" In this study we measured food intake and difference in weight gain in sexually regressed female goldfish intraperitionally injected with fluoxetine, a selective serotonin reuptake inhibitor (SSRI)."	7.75	Fluoxetine affects weight gain and expression of feeding peptides in the female goldfish brain. ( Chang, JP; Harris, EA; Mennigen, JA; Moon, TW; Trudeau, VL, 2009)
"These data suggest that fluoxetine and olanzapine treatment decreases weight gain in rats; a pharmacodynamic event-related effect that differs considerably from what is observed in the clinical condition."	7.72	Weight loss dynamics during combined fluoxetine and olanzapine treatment. ( Chabla, JM; Hallas, BH; Horowitz, JM; Perrone, JA; Torres, G, 2004)
"The aim of the present study was to compare the toxic effects of fluoxetine (F) (8 and 16 mg/kg) and venlafaxine (V) (40 and 80 mg/kg) administered during the third week of pregnancy on early development of rats."	7.70	Postnatal development of rats exposed to fluoxetine or venlafaxine during the third week of pregnancy. ( Altenburg, SP; da-Silva, VA; Lindsey, CJ; Malheiros, LR; Thomaz, TG, 1999)
"Patients with major depressive disorder (MDD) treated with olanzapine in combination with fluoxetine (OFC) demonstrate robust improvement in their depressive symptoms."	6.71	Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. ( Andersen, SW; Clemow, DB; Corya, SA, 2005)
"Fluoxetine 60 mg/day was effective for a longer period than fluoxetine 20 mg/day or placebo in maintaining weight loss."	6.67	Fluoxetine: a randomized clinical trial in the maintenance of weight loss. ( Dornseif, BE; Fludzinski, LA; Goldstein, DJ; Levine, LR; Potvin, JH; Rampey, AH, 1993)
"Contrasting with the predicted anorexigenic effect of increasing brain serotonin signaling, long-term use of selective serotonin reuptake inhibitor (SSRI) antidepressants correlates with body weight (BW) gain."	5.62	Melanocortin 4 receptor stimulation prevents antidepressant-associated weight gain in mice caused by long-term fluoxetine exposure. ( Ducy, P; Friedman, JM; Ilanges, A; Marchildon, F; Ortuño, MJ; Pellegrino, K; Schneeberger, M, 2021)
"Recently, depression has been envisioned as more than an alteration in neurotransmitters centered around receptor signaling pathways."	5.46	Fluoxetine coupled with zinc in a chronic mild stress model of depression: Providing a reservoir for optimum zinc signaling and neuronal remodeling. ( Omar, NN; Tash, RF, 2017)
" Moreover, 20 mg/kg fluoxetine, administered subchronically, may lead to atypical effects of those commonly observed in the FST, highlighting the importance and impact of both environmental condition and dosing regimen in common animal models of depression."	5.42	Differential Rearing Alters Forced Swim Test Behavior, Fluoxetine Efficacy, and Post-Test Weight Gain in Male Rats. ( Arndt, DL; Cain, ME; Peterson, CJ, 2015)
"Postnatal weight gain was taken from pediatric records, and the frequency of side effects was measured by maternal response to the interview questionnaire."	5.30	Weight gain in infants breastfed by mothers who take fluoxetine. ( Anderson, PO; Chambers, CD; Dick, LM; Felix, RJ; Johnson, KA; Jones, KL; Thomas, RG, 1999)
"There is low-certainty evidence to suggest that metformin may be effective in preventing weight gain."	5.22	Pharmacological interventions for prevention of weight gain in people with schizophrenia. ( Agarwal, SM; Ahsan, ZA; Cohn, T; Duncan, MJ; Faulkner, GEJ; Hahn, M; Lockwood, JT; Remington, G; Stogios, N; Takeuchi, H; Taylor, VH, 2022)
"To determine whether fluoxetine can promote recovery and prolong time-to-relapse among patients with anorexia nervosa following weight restoration."	5.12	Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial. ( Attia, E; Carter, JC; Devlin, MJ; Kaplan, AS; Olmsted, M; Parides, M; Pike, KM; Roberto, CA; Rockert, W; Walsh, BT; Woodside, B, 2006)
"Significant weight gain is a side effect associated with olanzapine treatment in some patients."	5.10	Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. ( Bogenschutz, M; Bustillo, JR; Hammond, R; Keith, S; Lauriello, J; Parker, K; Rowland, L, 2003)
"These results suggest that fluoxetine coadministration is clinically ineffective and cannot attenuate olanzapine-induced weight gain."	5.10	Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. ( Fuchs, C; Gil-Ad, I; Maayan, R; Pashinian, A; Poyurovsky, M; Schneidman, M; Weizman, A, 2002)
"This study offers preliminary evidence that fluoxetine may be useful in improving outcome and preventing relapse of patients with anorexia nervosa after weight restoration."	5.09	Double-blind placebo-controlled administration of fluoxetine in restricting- and restricting-purging-type anorexia nervosa. ( Deep, D; Hsu, LK; Kaye, WH; McConaha, C; Nagata, T; Plotnicov, KH; Sokol, MS; Weise, J; Weltzin, TE, 2001)
"Fluoxetine's effect (30 mg, 60 mg, and placebo) on postcessation weight gain was studied among participants from a randomized, double-blind 10-week smoking cessation trial who met strict criteria for abstinence and drug levels."	5.09	Weight suppression and weight rebound in ex-smokers treated with fluoxetine. ( Borrelli, B; Keuthen, NJ; Kristeller, J; Niaura, R; Ockene, JK; Spring, B, 1999)
"Adding the atypical neuroleptic risperidone to a serotonin reuptake inhibitor (SRI) has benefited patients with treatment-refractory obsessive-compulsive disorder (OCD)."	5.09	Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. ( Elliott, MA; Koran, LM; Ringold, AL, 2000)
"Patients (N = 284) with major depressive disorder (DSM-IV) were randomly assigned to double-blind treatment with fluoxetine (N = 92), sertraline, (N = 96), or paroxetine (N = 96) for a total of 26 to 32 weeks."	5.09	Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. ( Fava, M; Hoog, SL; Judge, R; Koke, SC; Nilsson, ME, 2000)
"During up to 1 year of olanzapine therapy, either as monotherapy or in combination with lithium and/or fluoxetine, patients with bipolar disorder demonstrated significant improvement in mania and depression symptoms with a favorable safety profile."	5.09	Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. ( Gibson, PJ; Greaney, MG; Grundy, SL; Namjoshi, MA; Sanger, TM; Tohen, MF, 2001)
" The study evaluated the efficacy of amisulpride, fluoxetine and clomipramine at the beginning of the re-feeding phase of the treatment of restricting anorexia nervosa according to DSM-IV criteria."	5.09	A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics. ( Cavagnini, F; Clemente, A; Ferrari, VM; Laini, V; Lugo, F; Mantero, M; Mauri, MC; Redaelli, G; Ruggiero, GM; Zappulli, D, 2001)
" The authors of this study investigated predictors of relapse among 989 participants (60% women) in a randomized, double-blind, 10-week multicenter trial to determine the effect of fluoxetine (30 or 60 mg) versus placebo in combination with behavioral counseling for smoking cessation."	5.09	Influences of gender and weight gain on short-term relapse to smoking in a cessation trial. ( Borrelli, B; Hitsman, B; Niaura, R; Papandonatos, G; Spring, B, 2001)
"Acute therapy with fluoxetine is associated with modest weight loss."	5.09	Changes in weight during a 1-year trial of fluoxetine. ( Amsterdam, JD; Beasley, CM; Kim, Y; Michelson, D; Quitkin, FM; Reimherr, FW; Rosenbaum, JF; Sundell, KL; Zajecka, J, 1999)
"We tested whether 14 wk of dexfenfluramine (30 mg) or fluoxetine (40 mg) treatment would prevent weight gain after subjects quit smoking."	5.08	Efficacies of dexfenfluramine and fluoxetine in preventing weight gain after smoking cessation. ( el-Khoury, A; Goldberg, H; McDermott, J; Pingitore, R; Spring, B; Wurtman, J; Wurtman, R, 1995)
"The effect of fluoxetine hydrochloride, a 5-HT uptake inhibitor (60 mg/day PO), in preventing weight gain associated with nicotine reduction was investigated in participants in a double-blind, placebo-controlled smoking-cessation trial."	5.07	Effects of fluoxetine on weight gain and food intake in smokers who reduce nicotine intake. ( Lowenbergh, JM; Morrell, EM; Pomerleau, CS; Pomerleau, OF, 1991)
"The 2 older FDA-approved treatments for bipolar depression, olanzapine-fluoxetine combination (OFC) and quetiapine (QTP) monotherapy, were efficacious (response NNT=4 for OFC, NNT=6 for QTP), but similarly likely to yield harms (OFC weight gain NNH=6; QTP sedation/somnolence NNH=5)."	4.90	Balancing benefits and harms of treatments for acute bipolar depression. ( Calabrese, JR; Citrome, L; Dell'Osso, B; Frye, MA; Ketter, TA; Miller, S, 2014)
"In comorbid diabetes mellitus and depression, most evidence supports the use of fluoxetine in control of glucose handling."	4.81	Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. ( Goodnick, PJ, 2001)
"In this retrospective cohort study from participants in the Mayo Clinic RIGHT study who were prescribed citalopram, paroxetine, sertraline, or fluoxetine, our aim was to evaluate the association of metabolizer phenotype and total body weight after 6 months of SSRIs initiation."	4.12	Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study. ( Acosta, A; Bielinski, SJ; Camilleri, M; Cifuentes, L; Decker, PA; Gonzalez-Izundegui, D; Hurtado, MD; Moyer, AM; Ricardo-Silgado, ML; Singh, S, 2022)
" We compared the effects of chronic treatment with the preferential nNOS inhibitor 7-nitroindazole (7-NI) with those evoked by the conventional antidepressant fluoxetine on alterations that are considered as markers of depression (immobility in the forced swimming test, FST, decreased body weight gain and increased plasma corticosterone concentration) and cardiovascular changes caused by CVS."	3.81	Effects of nitric oxide synthesis inhibitor or fluoxetine treatment on depression-like state and cardiovascular changes induced by chronic variable stress in rats. ( Almeida, J; Crestani, CC; Duarte, JO; Oliveira, LA, 2015)
" The present studies determined how high-fat feeding and body weight gain alter the sensitivity to the feeding suppression and neural activation to a selective norepinephrine reuptake inhibitor, nisoxetine."	3.79	High-fat diet-induced alterations in the feeding suppression of low-dose nisoxetine, a selective norepinephrine reuptake inhibitor. ( Bello, NT; Cunha, PP; Verpeut, JL; Walters, AL, 2013)
"This report describes a case of 12-year-old identical twins with anorexia nervosa, one of whom was treated with olanzapine and the other with fluoxetine, while undergoing family therapy."	3.78	Differential weight restoration on olanzapine versus fluoxetine in identical twins with anorexia nervosa. ( Boutelle, K; Cromley, T; Duvvuri, V; Kaye, WH; Klabunde, M, 2012)
"Weight gain during olanzapine/fluoxetine combination (OFC) therapy is very common."	3.77	Early weight gain as a predictor of substantial weight gain with olanzapine/fluoxetine combination: an analysis of 2 adult studies in treatment-resistant depression. ( Case, M; Degenhardt, EK; Jamal, HH; Tormey, S, 2011)
"These data suggest that fluoxetine and olanzapine treatment decreases weight gain in rats; a pharmacodynamic event-related effect that differs considerably from what is observed in the clinical condition."	3.72	Weight loss dynamics during combined fluoxetine and olanzapine treatment. ( Chabla, JM; Hallas, BH; Horowitz, JM; Perrone, JA; Torres, G, 2004)
" Then, the authors also examined the effect of subchronic treatment for 21 days with fluoxetine on clozapine-induced hyperphagia and modulation of body weight and fat pad weights."	3.71	Studies on modulation of feeding behavior by atypical antipsychotics in female mice. ( Kaur, G; Kulkarni, SK, 2002)
"The aim of the present study was to compare the toxic effects of fluoxetine (F) (8 and 16 mg/kg) and venlafaxine (V) (40 and 80 mg/kg) administered during the third week of pregnancy on early development of rats."	3.70	Postnatal development of rats exposed to fluoxetine or venlafaxine during the third week of pregnancy. ( Altenburg, SP; da-Silva, VA; Lindsey, CJ; Malheiros, LR; Thomaz, TG, 1999)
"Patients with major depressive disorder (MDD) who failed to satisfactorily respond to ≥ 2 different antidepressants for ≥ 6 weeks within the current MDD episode were acutely treated for 6-8 weeks, followed by stabilization (12 weeks) on OFC."	2.79	Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder. ( Brunner, E; Landry, J; Osuntokun, O; Thase, ME; Tohen, M, 2014)
" Adverse events occurring in 10% of patients or more with adjunctive placebo or aripiprazole were akathisia (4."	2.73	The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. ( Berman, RM; Carson, WH; Fava, M; Hennicken, D; Marcus, RN; McQuade, RD; Simon, JS; Thase, ME; Trivedi, MH, 2008)
"Patients with major depressive disorder (MDD) treated with olanzapine in combination with fluoxetine (OFC) demonstrate robust improvement in their depressive symptoms."	2.71	Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. ( Andersen, SW; Clemow, DB; Corya, SA, 2005)
"Amitriptyline was dosed as follows: 8 mg/day for 6 days, 8 mg twice a day for 6 days, 20 mg/day for 6 days, and 20 mg twice a day for 45 days."	2.70	Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study. ( Alves, LA; Barbosa, JS; Krymchantowski, AV; Silva, MT, 2002)
"Fluoxetine 60 mg/day was effective for a longer period than fluoxetine 20 mg/day or placebo in maintaining weight loss."	2.67	Fluoxetine: a randomized clinical trial in the maintenance of weight loss. ( Dornseif, BE; Fludzinski, LA; Goldstein, DJ; Levine, LR; Potvin, JH; Rampey, AH, 1993)
"Weight gain was detected only in patients receiving amitryptiline."	2.66	Efficacy and tolerability of fluoxetine in the elderly: a double-blind study versus amitryptiline. ( Altamura, AC; Guercetti, G; Invernizzi, G; Percudani, M, 1989)
"Obesity is associated with considerable morbidity and decreased life expectancy."	2.41	Options for pharmacological management of obesity in patients treated with atypical antipsychotics. ( Sanders, TA; Taylor, D; Werneke, U, 2002)
"Comprehensive review of safety data from approximately 3500 patients who received nefazodone in premarketing clinical trials demonstrates the drug to be very well tolerated, with a favorable side effect profile compared with other antidepressant drugs."	2.39	The safety profile of nefazodone. ( Kaplita, SB; Marcus, RN; Roberts, DL; Robinson, DS; Seminara, JA; Smith, JM; Stringfellow, JC, 1996)
"Recently, depression has been envisioned as more than an alteration in neurotransmitters centered around receptor signaling pathways."	1.46	Fluoxetine coupled with zinc in a chronic mild stress model of depression: Providing a reservoir for optimum zinc signaling and neuronal remodeling. ( Omar, NN; Tash, RF, 2017)
"5-Fluorouracil (5-FU) is a cytostatic drug associated with chemotherapy-induced cognitive impairments that many cancer patients experience after treatment."	1.38	Fluoxetine counteracts the cognitive and cellular effects of 5-fluorouracil in the rat hippocampus by a mechanism of prevention rather than recovery. ( Bennett, G; ElBeltagy, M; Lyons, L; Wigmore, P, 2012)
" Chronic administration of an effective (fluoxetine) or putative antidepressant (corticotropin-releasing factor-1 (CRF1) antagonist, SSR125543) reversed all physical and behavioral effects."	1.35	Corticolimbic transcriptome changes are state-dependent and region-specific in a rodent model of depression and of antidepressant reversal. ( Belzung, C; Edgar, N; Griebel, G; Ibarguen-Vargas, Y; Leman, S; Sibille, E; Surget, A; Wang, Y, 2009)
"Fluoxetine-treated patients reported an increased frequency of weight gain and anger or aggression."	1.29	Postmarketing surveillance by patient self-monitoring: preliminary data for sertraline versus fluoxetine. ( Bryant, SG; Fisher, S; Kent, TA, 1995)

Research

Studies (68)

Authors

Clinical Trials (7)

Trial Overview

Trial Outcomes

Change in Weight Per Month During Treatment

Change Per Month in Psychological Symptoms During Treatment, Assessed With Beck Anxiety Inventory (BAI)

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (2.94)	18.7374
1990's	13 (19.12)	18.2507
2000's	30 (44.12)	29.6817
2010's	16 (23.53)	24.3611
2020's	7 (10.29)	2.80

Authors	Studies
Ortuño, MJ	1
Schneeberger, M	1
Ilanges, A	1
Marchildon, F	1
Pellegrino, K	1
Friedman, JM	1
Ducy, P	1
Ricardo-Silgado, ML	1
Singh, S	1
Cifuentes, L	1
Decker, PA	1
Gonzalez-Izundegui, D	1
Moyer, AM	1
Hurtado, MD	1
Camilleri, M	1
Bielinski, SJ	1
Acosta, A	1
Agarwal, SM	1
Stogios, N	1
Ahsan, ZA	1
Lockwood, JT	1
Duncan, MJ	1
Takeuchi, H	1
Cohn, T	1
Taylor, VH	2
Remington, G	1
Faulkner, GEJ	1
Hahn, M	1
Chirokikh, AA	3
Uddin, SMZ	3
Areikat, N	3
Jones, R	3
Duque, E	3
Connor, C	3
Hadjiargyrou, M	3
Thanos, PK	3
Komatsu, DE	3
Zhen, F	1
Yu, L	1
Wang, L	3
Wang, S	2
Lu, W	1
Wang, X	1
An, C	1
Nishimura, Y	1
Mabuchi, K	1
Omura, N	1
Igarashi, A	1
Miura, M	1
Mima, N	1
Negishi, H	1
Morimoto, K	1
Takamata, A	1
de Farias, NO	1
Oliveira, R	1
Moretti, PNS	1
E Pinto, JM	1
Oliveira, AC	1
Santos, VL	1
Rocha, PS	1
Andrade, TS	1
Grisolia, CK	1
Omar, NN	1
Tash, RF	1
Scabia, G	1
Barone, I	1
Mainardi, M	1
Ceccarini, G	1
Scali, M	1
Buzzigoli, E	1
Dattilo, A	1
Vitti, P	1
Gastaldelli, A	1
Santini, F	1
Pizzorusso, T	1
Maffei, L	1
Maffei, M	1
Lee, SH	1
Mastronardi, CA	1
Li, RW	1
Paz-Filho, G	1
Dutcher, EG	1
Lewis, MD	1
Vincent, AD	1
Smith, PN	1
Bornstein, SR	1
Licinio, J	1
Wong, ML	1
Tatar, O	1
Ilhan, N	2
Susam, S	1
Ozercan, IH	1
Bello, NT	1
Walters, AL	1
Verpeut, JL	1
Cunha, PP	1
Brunner, E	1
Tohen, M	1
Osuntokun, O	1
Landry, J	1
Thase, ME	2
Ketter, TA	1
Miller, S	1
Dell'Osso, B	1
Calabrese, JR	1
Frye, MA	1
Citrome, L	1
De Long, NE	1
Barry, EJ	1
Pinelli, C	1
Wood, GA	1
Hardy, DB	1
Morrison, KM	1
Gerstein, HC	1
Holloway, AC	1
Almeida, J	1
Duarte, JO	1
Oliveira, LA	1
Crestani, CC	1
Arndt, DL	1
Peterson, CJ	1
Cain, ME	1
da Silva Dias, IC	1
Carabelli, B	1
Ishii, DK	1
de Morais, H	1
de Carvalho, MC	1
Rizzo de Souza, LE	1
Zanata, SM	1
Brandão, ML	1
Cunha, TM	1
Ferraz, AC	1
Cunha, JM	1
Zanoveli, JM	1
Dong, Y	1
Zhou, Y	1
Chu, X	1
Chen, S	1
Chen, L	1
Yang, B	1
Zhang, X	1
Lou, J	1
Deng, Q	1
Cao, Z	1
Wang, J	1
Xie, J	1
Serdyuk, T	1
Li, S	1
He, L	1
Chen, X	1
Li, W	1
Surget, A	1
Wang, Y	1
Leman, S	1
Ibarguen-Vargas, Y	1
Edgar, N	1
Griebel, G	1
Belzung, C	1
Sibille, E	1
Kaplan, AS	2
Walsh, BT	2
Olmsted, M	2
Attia, E	2
Carter, JC	2
Devlin, MJ	2
Pike, KM	2
Woodside, B	2
Rockert, W	2
Roberto, CA	2
Parides, M	2
Iñiguez, SD	1
Warren, BL	1
Parise, EM	1
Alcantara, LF	1
Schuh, B	1
Maffeo, ML	1
Manojlovic, Z	1
Bolaños-Guzmán, CA	1
Mennigen, JA	2
Harris, EA	1
Chang, JP	1
Moon, TW	2
Trudeau, VL	2
Nanchen, D	1
Willi, C	1
Peytremann-Bridevaux, I	1
Burnand, B	1
Walther, MR	1
Sassine, J	1
Duvvuri, V	1
Cromley, T	1
Klabunde, M	1
Boutelle, K	1
Kaye, WH	2
Degenhardt, EK	1
Jamal, HH	1
Tormey, S	1
Case, M	1
Lyons, L	1
ElBeltagy, M	1
Bennett, G	1
Wigmore, P	1
Werneke, U	1
Taylor, D	1
Sanders, TA	1
Krymchantowski, AV	1
Silva, MT	1
Barbosa, JS	1
Alves, LA	1
Bustillo, JR	1
Lauriello, J	1
Parker, K	1
Hammond, R	1
Rowland, L	1
Bogenschutz, M	1
Keith, S	1
Maina, G	1
Albert, U	1
Salvi, V	1
Bogetto, F	1
Perrone, JA	1
Chabla, JM	1
Hallas, BH	1
Horowitz, JM	1
Torres, G	1
Menaster, M	1
Goldstein, DJ	1
Rampey, AH	1
Dornseif, BE	1
Levine, LR	1
Potvin, JH	1
Fludzinski, LA	1
Andersen, SW	1
Clemow, DB	1
Corya, SA	1
Theleritis, CG	1
Papadimitriou, GN	1
Papageorgiou, CC	1
Dikeos, DG	1
Masdrakis, V	1
Kostoulas, C	1
Psarros, C	1
Soldatos, CR	1
Gobshtis, N	1
Ben-Shabat, S	1
Fride, E	1
Marcus, RN	2
McQuade, RD	1
Carson, WH	1
Hennicken, D	1
Fava, M	2
Simon, JS	1
Trivedi, MH	1
Berman, RM	1
Spring, B	3
Wurtman, J	1
Wurtman, R	1
el-Khoury, A	1
Goldberg, H	1
McDermott, J	1
Pingitore, R	1
Fisher, S	1
Kent, TA	1
Bryant, SG	1
Cabrera, TM	1
Battaglia, G	1
Szarek, BL	1
Brandt, DM	1
Robinson, DS	1
Roberts, DL	1
Smith, JM	1
Stringfellow, JC	1
Kaplita, SB	1
Seminara, JA	1
Amsterdam, JD	2
Garcia-España, F	1
Goodman, D	1
Hooper, M	1
Hornig-Rohan, M	1
Borrelli, B	2
Niaura, R	2
Kristeller, J	1
Ockene, JK	1
Keuthen, NJ	1
da-Silva, VA	1
Altenburg, SP	1
Malheiros, LR	1
Thomaz, TG	1
Lindsey, CJ	1
Michelson, D	1
Quitkin, FM	1
Reimherr, FW	1
Rosenbaum, JF	1
Zajecka, J	1
Sundell, KL	1
Kim, Y	1
Beasley, CM	1
Chambers, CD	1
Anderson, PO	1
Thomas, RG	1
Dick, LM	1
Felix, RJ	1
Johnson, KA	1
Jones, KL	1
Sansone, RA	1
Wiederman, MW	1
Shrader, JA	1
Cash, TF	1
Brown, MA	1
Koran, LM	1
Ringold, AL	1
Elliott, MA	1
Judge, R	1
Hoog, SL	1
Nilsson, ME	1
Koke, SC	1
Franco, K	1
Malhotra, S	1
Nagata, T	1
Weltzin, TE	1
Hsu, LK	1
Sokol, MS	1
McConaha, C	1
Plotnicov, KH	1
Weise, J	1
Deep, D	1
Sanger, TM	1
Grundy, SL	1
Gibson, PJ	1
Namjoshi, MA	1
Greaney, MG	1
Tohen, MF	1
Ruggiero, GM	1
Laini, V	1
Mauri, MC	1
Ferrari, VM	1
Clemente, A	1
Lugo, F	1
Mantero, M	1
Redaelli, G	1
Zappulli, D	1
Cavagnini, F	1
Goodnick, PJ	1
Hitsman, B	1
Papandonatos, G	1
Calil, HM	1
Kaur, G	1
Kulkarni, SK	1
Poyurovsky, M	1
Pashinian, A	1
Gil-Ad, I	1
Maayan, R	1
Schneidman, M	1
Fuchs, C	1
Weizman, A	1
Oliveros, SC	1
Iruela, LM	1
Caballero, L	1
Baca, E	1
Pomerleau, OF	1
Pomerleau, CS	1
Morrell, EM	1
Lowenbergh, JM	1
Altamura, AC	1
Percudani, M	1
Guercetti, G	1
Invernizzi, G	1
Brady, K	1
Zarzar, M	1
Lydiard, RB	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Comparison of Bupropion SR and Placebo for Smoking Cessation[NCT00176449]	Phase 4	52 participants (Actual)	Interventional	2001-04-30	Completed
Fluoxetine After Weight Restoration in Anorexia Nervosa[NCT00288574]	Phase 4	93 participants (Actual)	Interventional	2000-01-31	Completed
A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder[NCT00095758]	Phase 3	1,200 participants	Interventional	2004-09-30	Completed
A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy (ADT) Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior ADT[NCT00683852]	Phase 3	225 participants (Actual)	Interventional	2008-09-30	Completed
[NCT00113737]		0 participants	Interventional	1998-02-28	Completed
[NCT00113711]		0 participants	Interventional	1995-01-31	Completed
Feasibility of Using Holographic Memory Resolution® (HMR) in Patients/Clients With Pain[NCT05001399]		60 participants (Actual)	Interventional	2021-10-25	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	kg per month (Mean)
Fluoxetine	-1.94
Placebo	-2.14

The Beck Anxiety Inventory is a 21 question self-report measure of anxiety symptoms during the past week. Possible scores range from 0 - 63, with higher scores indicating more severe symptoms. Random effects regression models were used to compare fluoxetine vs placebo groups over time, using data from all patients. (NCT00288574)
Timeframe: 12 months

Change Per Month in Psychological Symptoms During Treatment, Assessed With Beck Depression Inventory (BDI)

Intervention	units on a scale (Mean)
Fluoxetine	-0.70
Placebo	-0.22

The Beck Depression Inventory-II is a 21 question self-report measure of depressive symptoms. Possible scores range from 0 - 63, with higher scores indicating more severe symptoms.Random effects regression models were used to compare fluoxetine vs placebo groups over time, using data from all patients. (NCT00288574)
Timeframe: 12 months

Change Per Month in Psychological Symptoms During Treatment, Assessed With the Eating Disorders Inventory (EDI), Body Dissatisfaction Subscale.

Intervention	units on a scale (Mean)
Fluoxetine	0.12
Placebo	0.20

The EDI is a 64 item self-report measure of psychological and behavioral characteristics of eating disorders. The Body Dissatisfaction subscale is comprised of nine items indicating the belief that parts of the body are too large. Possible scores range from 0 to 27, with higher scores indicating greater dissatisfaction. Random effects regression models were used to compare fluoxetine vs placebo groups over time, using data from all patients. (NCT00288574)
Timeframe: 12 months

Change Per Month in Psychological Symptoms During Treatment, Assessed With the Eating Disorders Inventory (EDI), Bulimia Subscale.

Intervention	units on a scale (Mean)
Fluoxetine	-0.24
Placebo	-0.26

The EDI is a 64 item self-report measure of psychological and behavioral characteristics of eating disorders. The Bulimia subscale is comprised of seven items indicating the tendency towards episodes of uncontrollable overeating (binge eating). Possible scores range from 0 to 21, with higher scores indicating greater tendency. Random effects regression models were used to compare fluoxetine vs placebo groups over time, using data from all patients. (NCT00288574)
Timeframe: 12 months

Change Per Month in Psychological Symptoms During Treatment, Assessed With the Eating Disorders Inventory (EDI), Drive for Thinness Subscale.

Intervention	units on a scale (Mean)
Fluoxetine	-0.11
Placebo	0.035

The EDI is a 64 item self-report measure of psychological and behavioral characteristics of eating disorders. The Drive for Thinness subscale is comprised of seven items indicating excessive concern with dieting, preoccupation with weight and entrenchment in an extreme pursuit of thinness. Possible scores range from 0 to 21, with higher scores indicating greater Drive for Thinness. Random effects regression models were used to compare fluoxetine vs placebo groups over time, using data from all patients. (NCT00288574)
Timeframe: 12 months

Change Per Month in Psychological Symptoms During Treatment, Assessed With the Eating Disorders Inventory (EDI), Perfectionism Subscale.

Intervention	units on a scale (Mean)
Fluoxetine	-0.24
Placebo	-0.81

The EDI is a 64 item self-report measure of psychological and behavioral characteristics of eating disorders. The Perfectionism subscale is comprised of six items Indicating excessive personal expectations for superior achievement. Possible scores range from 0 to 18, with higher scores indicating greater expectations. Random effects regression models were used to compare fluoxetine vs placebo groups over time, using data from all patients. (NCT00288574)
Timeframe: 12 months

Change Per Month in Psychological Symptoms During Treatment, Assessed With the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q).

Intervention	units on a scale (Mean)
Fluoxetine	-0.037
Placebo	0.05

The Q-LES-Q is a 93 item self-report measure of enjoyment and satisfaction experienced by individuals in various areas of daily functioning. Each of the 93 items is scored on a five-point scale, and the total score is converted to a percentage of the maximum score possible. The range is therefore from 0 to 100, with a higher score indicating greater enjoyment or satisfaction. Random effects regression models were used to compare fluoxetine vs placebo groups over time, using data from all patients. (NCT00288574)
Timeframe: 12 months

Change Per Month in Psychological Symptoms During Treatment, Assessed With the Rosenberg Self-Esteem Scale (RSES).

Intervention	percentage of maximum possible score (Mean)
Fluoxetine	0.23
Placebo	0.31

The RSES is a 10 item self-report measure of self-esteem. Possible scores range from 0 - 30, with lower scores indicating more severe symptoms. Random effects regression models were used to compare fluoxetine vs placebo groups over time, using data from all patients. (NCT00288574)
Timeframe: 12 months

Change Per Month in Psychological Symptoms During Treatment, Assessed With the Yale Brown Cornell Obsessive Compulsive Scale for Eating Disorders (YBC-EDS)

Intervention	units on a scale (Mean)
Fluoxetine	0.12
Placebo	0.07

The YBC-EDS is an eight item, clinician-rated instrument assessing eating related preoccupations and/or rituals. Possible scores range from 0 to 32, with higher scores indicating greater preoccupations. Random effects regression models were used to compare fluoxetine vs placebo groups over time, using data from all patients. (NCT00288574)
Timeframe: 12 months

Proportion of Patients Remaining in Study at 1 Year

Intervention	units on a scale (Mean)
Fluoxetine	-0.18
Placebo	0.028

The primary outcome measure was the proportion of patients with AN successfully completing 1 year of treatment and maintaining > 85% Ideal Body Weight. (NCT00288574)
Timeframe: 12 months

MADRS (Montgomery-Asberg Depression Rating Scale) Readmission Rate

Intervention	proportion of participants (Number)
Fluoxetine	0.265
Placebo	0.315

MADRS readmission rate is defined as MADRS score<11. The 10-item Montgomery-Asberg Depression Rating Scale (MADRS), which measures depression severity over the past week, was completed by clinicians using an MGH structured interview. Each item is measured on a scale from 0 to 6, and the items are summed to find the total score. The total minimum score is 0 units on a scale and the total maximum score is 60 units on a scale, where higher scores indicate more severe depression. (NCT00683852)
Timeframe: 12 weeks

MADRS (Montgomery-Asberg Depression Rating Scale) Response Rate

Intervention	Participants (Count of Participants)
Phase 1 Drug	4
Phase 1 Placebo Non-Responders on Drug in Phase 2	8
Phase I Placebo	16
Phase 1 Placebo Non-Responders on Placebo in Phase 2	4

The primary outcome was the difference in response rate (decrease in MADRS total score of at least 50%) using the SPCD (sequential parallel comparison design). The 10-item Montgomery-Asberg Depression Rating Scale (MADRS), which measures depression severity over the past week, was completed by clinicians using an MGH structured interview. Each item is measured on a scale from 0 to 6, and the items are summed to find the total score. The total minimum score is 0 units on a scale and the total maximum score is 60 units on a scale, where higher scores indicate more severe depression. (NCT00683852)
Timeframe: 12 weeks

Mean Change in Clinical Global Impression of Severity (CGI-S)

Intervention	Participants (Count of Participants)
Phase 1 Drug	10
Phase 1 Placebo Non-Responders on Drug in Phase 2	11
Phase I Placebo	29
Phase 1 Placebo Non-Responders on Placebo in Phase 2	5

The CGI-S scale was administered by clinicians based on assessment of the patient's clinical status. They measured, based on history and scores on other instruments, depressive severity. It consists of one question scored on a seven-point scale (1 = normal to 7 = among the most severe), so a higher total score indicates greater depressive severity. The minimum score is 1, and the maximum score is 7. (NCT00683852)
Timeframe: Baseline and 12 weeks

Mean Change in MADRS (Montgomery-Asberg Depression Rating Scale) Score From Baseline to the End of Follow-up

Intervention	units on a scale (Mean)
Phase 1 Drug	-0.81
Phase 1 Placebo Non-Responders on Drug in Phase 2	-0.64
Phase I Placebo	-0.84
Phase 1 Placebo Non-Responders on Placebo in Phase 2	-0.43

The 10-item Montgomery-Asberg Depression Rating Scale (MADRS), which measures depression severity over the past week, was completed by clinicians using an MGH structured interview. Each item is measured on a scale from 0 to 6, and the items are summed to find the total score. The total minimum score is 0 units on a scale and the total maximum score is 60 units on a scale, where higher scores indicate more severe depression. (NCT00683852)
Timeframe: Baseline and 12 Weeks

Number of Patients With Treatment Emergent AEs in Two Treatment Groups - People Exclusively on Drug or Placebo Throughout the Study

Intervention	units on a scale (Mean)
Phase 1 Drug	-8.54
Phase 1 Placebo Non-Responders on Drug in Phase 2	-5.80
Phase I Placebo	-8.09
Phase 1 Placebo Non-Responders on Placebo in Phase 2	-3.32

Differences in the incidence of treatment emergent AEs between the treatment groups were examined and evaluated using descriptive statistics. This analysis compared AEs between the arms that received exclusively drug throughout the study or placebo throughout the study. (NCT00683852)
Timeframe: 12 Weeks

Number of Patients With Treatment Emergent AEs in Two Treatment Groups - Placebo Non-Responders

Intervention	Patients (Number)
ADAPT Drug/Drug Group	39
ADAPT Placebo/Placebo Group	60

Differences in the incidence of treatment emergent AEs between the treatment groups were examined and evaluated using descriptive statistics. This analysis focused on placebo non-responders in phase 1 and presented them by their treatment assignment in phase 2. (NCT00683852)
Timeframe: 12 Weeks

Treatment Emergent AEs in Two Treatment Groups - Safety Sample

Intervention	Patients (Number)
Phase 1 Placebo Non-Responders on Drug in Phase 2	40
Phase 1 Placebo Non-Responders on Placebo in Phase 2	44

Differences in the incidence of treatment emergent AEs between the treatment groups were examined and evaluated using descriptive statistics. In this analysis, AEs were summarized according to person-phase of occurrence. Each AE was attributed to the person and then to phase 1 or phase 2, depending on the initial date of onset. (NCT00683852)
Timeframe: 12 Weeks

Mean Change in Symptom Questionnaire (SQ)

Intervention	adverse events (Number)
ADAPT Drug Group	58
ADAPT Placebo Group	110

The SQ, a 92-item (yes/no) self-rating questionnaire, includes 4 distress and 4 well-being subscales. There are 68 items for the distress subscales and 24 items for the well-being subscales. Each item has either a Yes/No or True/False answer. For the distress symptom score, add together the following items and score 1 when the answer is Yes/True: 1, 2, 3, 5, 6, 8, 11, 12, 15, 18, 20, 22, 24, 25, 26, 27, 28, 29, 30, 32, 33, 34, 36, 37, 39, 41, 42, 44, 45, 47, 48, 49, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 72, 73, 74, 75, 76, 77, 79, 80, 81, 82, 84, 85, 86, 87, 88, 90, 91, 92. Minimum score is 0 and maximum score is 68. A higher score indicates more distress symptoms. For the well-being subscale score, add together the following items and score 1 when the answer is No/False: 4, 7, 9, 10, 13, 14, 16, 17, 19, 21, 23, 29, 31, 35, 38, 40, 43, 46, 50, 51, 71, 78, 83, 89. Minimum score is 0 and maximum score is 24. A higher score indicates more well-being. (NCT00683852)
Timeframe: Baseline and 12 weeks

Intervention	units on a scale (Mean)
	Sum of 4 subscaled distress scores	Sum of 4 subscaled well-being scores
Phase 1 Drug	-9.44	3.71
Phase 1 Placebo Non-Responders on Drug in Phase 2	-6.78	3.34
Phase 1 Placebo Non-Responders on Placebo in Phase 2	-4.52	1.98
Phase I Placebo	-9.70	2.75

Article	Year
Melanocortin 4 receptor stimulation prevents antidepressant-associated weight gain in mice caused by long-term fluoxetine exposure. The Journal of clinical investigation, 2021, 12-15, Volume: 131, Issue:24 Topics: Animals; Antidepressive Agents; Cell Line; Fluoxetine; Humans; Mice; Mice, Knockout; Pro-Opiomelanoc	2021
Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study. BMC medicine, 2022, 07-26, Volume: 20, Issue:1 Topics: Body Weight; Citalopram; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6;	2022
Combined methylphenidate and fluoxetine treatment in adolescent rats significantly impairs weight gain with minimal effects on skeletal development. Bone, 2023, Volume: 167 Topics: Animals; Body Weight; Fluoxetine; Male; Methylphenidate; Rats; Rats, Sprague-Dawley; Weight Gain	2023
Combined methylphenidate and fluoxetine treatment in adolescent rats significantly impairs weight gain with minimal effects on skeletal development. Bone, 2023, Volume: 167 Topics: Animals; Body Weight; Fluoxetine; Male; Methylphenidate; Rats; Rats, Sprague-Dawley; Weight Gain	2023
Combined methylphenidate and fluoxetine treatment in adolescent rats significantly impairs weight gain with minimal effects on skeletal development. Bone, 2023, Volume: 167 Topics: Animals; Body Weight; Fluoxetine; Male; Methylphenidate; Rats; Rats, Sprague-Dawley; Weight Gain	2023
Combined methylphenidate and fluoxetine treatment in adolescent rats significantly impairs weight gain with minimal effects on skeletal development. Bone, 2023, Volume: 167 Topics: Animals; Body Weight; Fluoxetine; Male; Methylphenidate; Rats; Rats, Sprague-Dawley; Weight Gain	2023
Salvianolic Acids Alleviate Chronic Mild Stress-Induced Depressive-Like Behaviors in Rats. Journal of integrative neuroscience, 2023, May-08, Volume: 22, Issue:3 Topics: Animals; Disease Models, Animal; Fluoxetine; Hippocampus; Male; Myeloid Differentiation Factor 88; R	2023
Fluoxetine Mimics the Anorectic Action of Estrogen and Its Regulation of Circadian Feeding in Ovariectomized Female Rats. Nutrients, 2020, Mar-22, Volume: 12, Issue:3 Topics: Animals; Appetite Depressants; Circadian Rhythm; Estrogens; Feeding Behavior; Female; Fluoxetine; Ov	2020
Fluoxetine chronic exposure affects growth, behavior and tissue structure of zebrafish. Comparative biochemistry and physiology. Toxicology & pharmacology : CBP, 2020, Volume: 237 Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Fluoxetine; Intestinal Mucosa;	2020
Fluoxetine coupled with zinc in a chronic mild stress model of depression: Providing a reservoir for optimum zinc signaling and neuronal remodeling. Pharmacology, biochemistry, and behavior, 2017, Volume: 160 Topics: Animals; Antidepressive Agents, Second-Generation; Brain; Chronic Disease; Corticosterone; Depressio	2017
The antidepressant fluoxetine acts on energy balance and leptin sensitivity via BDNF. Scientific reports, 2018, 01-29, Volume: 8, Issue:1 Topics: Adipose Tissue, White; Animals; Antidepressive Agents; Body Weight; Brain-Derived Neurotrophic Facto	2018
Short-term antidepressant treatment has long-lasting effects, and reverses stress-induced decreases in bone features in rats. Translational psychiatry, 2019, 01-16, Volume: 9, Issue:1 Topics: Animals; Antidepressive Agents; Behavior, Animal; Bone Density; Disease Models, Animal; Fluoxetine;	2019
Is there any potential anticancer effect of raloxifene and fluoxetine on DMBA-induced rat breast cancer? Journal of biochemical and molecular toxicology, 2019, Volume: 33, Issue:9 Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Body Weight; Carcinogens; Enzyme-L	2019
High-fat diet-induced alterations in the feeding suppression of low-dose nisoxetine, a selective norepinephrine reuptake inhibitor. Journal of obesity, 2013, Volume: 2013 Topics: Animals; Appetite Regulation; Arcuate Nucleus of Hypothalamus; Blood Pressure; Diet, High-Fat; Dose-	2013
Antenatal exposure to the selective serotonin reuptake inhibitor fluoxetine leads to postnatal metabolic and endocrine changes associated with type 2 diabetes in Wistar rats. Toxicology and applied pharmacology, 2015, May-15, Volume: 285, Issue:1 Topics: Adiposity; Animals; Blood Glucose; Chemical and Drug Induced Liver Injury; Chemokine CCL2; Diabetes	2015
Effects of nitric oxide synthesis inhibitor or fluoxetine treatment on depression-like state and cardiovascular changes induced by chronic variable stress in rats. Stress (Amsterdam, Netherlands), 2015, Volume: 18, Issue:4 Topics: Animals; Antidepressive Agents; Autonomic Nervous System; Baroreflex; Behavior, Animal; Cardiovascul	2015
Differential Rearing Alters Forced Swim Test Behavior, Fluoxetine Efficacy, and Post-Test Weight Gain in Male Rats. PloS one, 2015, Volume: 10, Issue:7 Topics: Animals; Behavior, Animal; Fluoxetine; Male; Motor Activity; Rats, Sprague-Dawley; Swimming; Weight	2015
Indoleamine-2,3-Dioxygenase/Kynurenine Pathway as a Potential Pharmacological Target to Treat Depression Associated with Diabetes. Molecular neurobiology, 2016, Volume: 53, Issue:10 Topics: Animals; Antidepressive Agents; Behavior, Animal; Blood Glucose; Cytokines; Depression; Diabetes Mel	2016
Dental noise exposed mice display depressive-like phenotypes. Molecular brain, 2016, 05-10, Volume: 9, Issue:1 Topics: Animals; Antidepressive Agents; Behavior, Animal; Choice Behavior; Dentistry; Depression; Fluoxetine	2016
Corticolimbic transcriptome changes are state-dependent and region-specific in a rodent model of depression and of antidepressant reversal. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2009, Volume: 34, Issue:6 Topics: Affect; Agonistic Behavior; Amygdala; Animals; Antidepressive Agents; Brain; Corticotropin-Releasing	2009
Nicotine exposure during adolescence induces a depression-like state in adulthood. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2009, Volume: 34, Issue:6 Topics: Aging; Animals; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Cholinergic Agents; De	2009
Fluoxetine affects weight gain and expression of feeding peptides in the female goldfish brain. Regulatory peptides, 2009, Jun-05, Volume: 155, Issue:1-3 Topics: Animals; Brain; Corticotropin-Releasing Hormone; Eating; Female; Fluoxetine; Goldfish; Growth Hormon	2009
[Preventing weight gain in smoking cessation: there is no miracle solution]. Revue medicale suisse, 2009, Aug-05, Volume: 5, Issue:212 Topics: Adult; Bupropion; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Female; Fluoxetine; Humans;	2009
Waterborne fluoxetine disrupts feeding and energy metabolism in the goldfish Carassius auratus. Aquatic toxicology (Amsterdam, Netherlands), 2010, Oct-01, Volume: 100, Issue:1 Topics: Animals; Behavior, Animal; Corticotropin-Releasing Hormone; Eating; Energy Metabolism; Feeding Behav	2010
Differential weight restoration on olanzapine versus fluoxetine in identical twins with anorexia nervosa. The International journal of eating disorders, 2012, Volume: 45, Issue:2 Topics: Anorexia Nervosa; Benzodiazepines; Child; Diseases in Twins; Family Therapy; Female; Fluoxetine; Hum	2012
Early weight gain as a predictor of substantial weight gain with olanzapine/fluoxetine combination: an analysis of 2 adult studies in treatment-resistant depression. Journal of clinical psychopharmacology, 2011, Volume: 31, Issue:3 Topics: Benzodiazepines; Controlled Clinical Trials as Topic; Depression; Drug Combinations; Drug Resistance	2011
Fluoxetine counteracts the cognitive and cellular effects of 5-fluorouracil in the rat hippocampus by a mechanism of prevention rather than recovery. PloS one, 2012, Volume: 7, Issue:1 Topics: Animals; Antidepressive Agents, Second-Generation; Antimetabolites, Antineoplastic; Body Weight; Bro	2012
Weight loss dynamics during combined fluoxetine and olanzapine treatment. BMC pharmacology, 2004, Oct-21, Volume: 4 Topics: Animals; Benzodiazepines; Fluoxetine; Male; Olanzapine; Rats; Rats, Long-Evans; Selective Serotonin	2004
Use of olanzapine in anorexia nervosa. The Journal of clinical psychiatry, 2005, Volume: 66, Issue:5 Topics: Anorexia Nervosa; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Fluoxetine; Human	2005
Excessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report. BMC psychiatry, 2006, Sep-05, Volume: 6 Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Bulimia; Depression; Diabetes	2006
Antidepressant-induced undesirable weight gain: prevention with rimonabant without interference with behavioral effectiveness. European journal of pharmacology, 2007, Jan-12, Volume: 554, Issue:2-3 Topics: Analysis of Variance; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Desipramine; Female	2007
Postmarketing surveillance by patient self-monitoring: preliminary data for sertraline versus fluoxetine. The Journal of clinical psychiatry, 1995, Volume: 56, Issue:7 Topics: 1-Naphthylamine; Adult; Adverse Drug Reaction Reporting Systems; Aggression; Ambulatory Care; Confid	1995
Delayed decreases in brain 5-hydroxytryptamine2A/2C receptor density and function in male rat progeny following prenatal fluoxetine. The Journal of pharmacology and experimental therapeutics, 1994, Volume: 269, Issue:2 Topics: Adrenocorticotropic Hormone; Amphetamines; Animals; Cerebral Cortex; Female; Fluoxetine; Hypothalamu	1994
A comparison of weight changes with fluoxetine, desipramine, and amitriptyline: a retrospective study of psychiatric inpatients. The Journal of nervous and mental disease, 1993, Volume: 181, Issue:11 Topics: Amitriptyline; Body Weight; Desipramine; Dose-Response Relationship, Drug; Drug Therapy, Combination	1993
Breast enlargement during chronic antidepressant therapy. Journal of affective disorders, 1997, Volume: 46, Issue:2 Topics: Breast; Breast Diseases; Cyclohexanols; Depressive Disorder; Female; Fluoxetine; Humans; Hyperplasia	1997
Postnatal development of rats exposed to fluoxetine or venlafaxine during the third week of pregnancy. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 1999, Volume: 32, Issue:1 Topics: Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Birth Weight; Body Weight; Cycl	1999
Weight gain in infants breastfed by mothers who take fluoxetine. Pediatrics, 1999, Volume: 104, Issue:5 Topics: Antidepressive Agents, Second-Generation; Breast Feeding; Cohort Studies; Female; Fluoxetine; Humans	1999
Naturalistic study of the weight effects of amitriptyline, fluoxetine, and sertraline in an outpatient medical setting. Journal of clinical psychopharmacology, 2000, Volume: 20, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Amitriptyline; Antidepressive Agents, Second-Genera	2000
Fluoxetine (Sarafem) for premenstrual dysphoric disorder. The Medical letter on drugs and therapeutics, 2001, Jan-22, Volume: 43, Issue:1096 Topics: Adult; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder; Dose-Response Relationship, Dru	2001
Poststroke depression. The American journal of psychiatry, 2001, Volume: 158, Issue:4 Topics: Aged; Antidepressive Agents, Tricyclic; Depressive Disorder; Fluoxetine; Humans; Middle Aged; Nortri	2001
Studies on modulation of feeding behavior by atypical antipsychotics in female mice. Progress in neuro-psychopharmacology & biological psychiatry, 2002, Volume: 26, Issue:2 Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adipose Tissue; Animals; Antipsychotic A	2002
Fluoxetine-induced anorexia in a bulimic patient. The American journal of psychiatry, 1992, Volume: 149, Issue:8 Topics: Adult; Amenorrhea; Anorexia Nervosa; Bulimia; Female; Fluoxetine; Humans; Recurrence; Weight Gain	1992
Fluoxetine in panic disorder patients with imipramine-associated weight gain. Journal of clinical psychopharmacology, 1989, Volume: 9, Issue:1 Topics: Adult; Agoraphobia; Depressive Disorder; Fear; Female; Fluoxetine; Humans; Imipramine; Middle Aged;	1989

fluoxetine and Weight Gain